Last updated on April 19, 2014 at 9:20 EDT

Health Robotics Reports 106 Total New Sales in 2012, Including 27 New Sales in 4Q, Beating FY2011 Record

February 14, 2013

BOZEN, Sud-Tirol, Italy, February 14, 2013 /PRNewswire/ –

For FY2012 Health Robotics today reported 39 new Robot sales [22 for Oncology, and 17
for non-hazardous IVs] plus 67 i.v.SOFT workflow software contracts, making 2012 yet
another record year. For 4Q2012, the company reported 27 new contracts, including 11 I.V.
Robots (5 for Oncology Therapy, and 6 for non-hazardous IVs) and 16 i.v.SOFT workflow
software agreements, continuing its 4-year supremacy of the world’s Sterile Compounding
Automation market. Now reaching over 350 total installations in the world [including over
90% of Oncology IV Robots global market share, and over 80% of total IV Robots global
market share], Health Robotics continued to benefit in 2012 from its transition to a
direct sales and service approach, now accounting for the majority of its gross revenues
and profits.

Gaspar DeViedma, Health Robotics’ Executive Vice President and Board Member, stated:
“I’m very pleased with 2012 results, especially considering my 5-month medical leave of
absence, and the effects of global economic crisis in some regions of the world.
Auspiciously, Health-System pharmacists continue to recognize the undeniable fact that
Health Robotics’ second generation modular architecture of integrated and networked
medical devices are fully automated, offer 3 to 4 times faster speed/throughput, for less
than half the price, size, and weight than any of its global competitors[1], and
delivering payback periods/R.O.I. of less than 1 year.”

During last quarter, Health Robotics and/or some of its global partners signed up 27
new installations under contract at: Brigham & Women’s Hospital, LeeSar Sterile
Compounding Center (Florida), University of Tennessee Medical Center, University of
Chicago Hospital, Hospital of the University of Pennsylvania, University Hospital of Ghent
(Belgium), Goes Scheldezoom (Netherlands), Hamad Medical Corporation’ Al-Wakrah Hospital
(Qatar), King Khaled Hospital of the Ministry of Health (Hail, Saudi Arabia), and Etlik
Hospital (Turkey), amongst others.

Mr. DeViedma concluded: “Health Robotics’ 4Q and full year performance reflects a
healthy mix of additional Robot and IV workflow sales to its pre-existing customers, as
well as new sales to new Health-System pharmacies. Of particular interest to me is the
expansion into Saudi Arabia and Qatar by replacing Olayan-AHCSC due to its poor service
record and customer complaints, the explosion in i.v.SOFT contracts in USA and Benelux,
and finally the replacement of CytoCare with the launch of i.v.STATION ONCO in selected
countries where syringes and IV Bags are the norm, instead of the IV Bottles still
supported by the CytoCare robot.”

About Health Robotics:

Founded in 2006 and now reaching over 80% total IV Robots market share in the world
[including over 90% of the Oncology Robots global market], Health Robotics is the
undisputed leading supplier of life-critical intravenous medication robots, providing over
350 hospital installations in 5 continents with the only fully-integrated robotics-based
technology, IV Workflow, and manual compounding software automation solutions. Health
Robotics’ second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have
been found [through scientific and peer-reviewed studies[2],[3]] to greatly contribute to
ease hospitals’ growing pressures to improve patient safety[2], increase throughput, and
contain costs[2]. Through the effective and efficient production of sterile, accurate,
tamper-evident and ready-to-administer IVs, Health Robotics’ medical devices and
integrated workflow solutions help hospitals eliminate life-threatening drug[2] and
diluent[2] exchange errors, improve drug potency[3], decrease other medical mistakes and
sterility risks, work more efficiently[2], reduce waste and controlled substances’
diversion, and diminish the gap between rising patient volume/acuity and scarce nursing,
and pharmacy staff. For more information, please visit: http://www.health-robotics.com


1. Competitors: Intelligent Hospital Systems/RIVA, Fresenius Kabi/MDS, Baxter/Baxa,
and Loccioni.


2. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger,
Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and
Rothschild. Brigham & Women’s Hospital, Massachusetts College of Pharmacy, and Harvard
Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

3. Validation of an automated method for compounding monoclonal antibody patient
doses: case studies of Avastin(R), Remicade(R), and Herceptin(R). Peters, Capelle,
Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

        For additional information, please contact:

        Claudia Perez
        Phone +1-786-417-1251

SOURCE Health Robotics

Source: PR Newswire